ArticleFrontiers in immunology2026
Exploring the mechanism by which modified huangqi chifeng decoction protects podocytes via Arid5a-mediated transcriptional regulation of the AIM2 pyroptosis signaling axis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic kidney disease (CKD) is a major global health burden with substantial morbidity and mortality. Proteinuria is strongly associated with adverse renal outcomes, and podocyte pyroptosis is increasingly recognized as a key driver of glomerular filtration barrier disruption. Objective: This study sought to elucidate how Modified Huangqi Chifeng Decoction (MHCD) mitigates renal and podocyte injury by modulating the Arid5a/AIM2-dependent pyroptosis pathway. Materials and methods: An adriamycin-induced nephropathy (ADR) rat model and an Results: MHCD markedly reduced proteinuria, alleviated renal histopathological damage, and improved podocyte viability in ADR rats. These protective effects coincided with downregulation of Arid5a, AIM2, and downstream pyroptosis mediators-including Caspase-1, ASC oligomers, GSDMD, IL-1β, and IL-18. Mechanistically, Arid5a functioned as a transcription factor that binds to the AIM2 promoter to regulate AIM2 expression. Conclusions: MHCD mitigates renal and podocyte injury by suppressing inflammasome activation and pyroptosis through Arid5a-mediated transcriptional activation of the AIM2 signaling axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.